News >

Onartuzumab Shows No Additional Benefit When Combined With Bevacizumab in GBM

Lisa Miller
Published: Friday, Dec 23, 2016

Timothy Cloughesy, MD

Timothy Cloughesy, MD

The addition of onartuzumab to bevacizumab (Avastin) did not provide any increased clinical benefit in the treatment of patients with recurrent glioblastoma multiforme (GBM), according to the results of a study published in the Journal of Clinical Oncology1.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication